BLUE's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 430.72 -- higher than 92.3% of US-listed equities with positive expected earnings growth.
With a price/sales ratio of 14.29, bluebird bio Inc has a higher such ratio than 90.16% of stocks in our set.
Revenue growth over the past 12 months for bluebird bio Inc comes in at 323.89%, a number that bests 97.95% of the US stocks we're tracking.
If you're looking for stocks that are quantitatively similar to bluebird bio Inc, a group of peers worth examining would be RARE, ZYME, APTX, CLLS, and RGNX.
Bluebird Bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies. The company was founded in 1992 and is based in Cambridge, Massachusetts.
The European Medicines Agency ((EMA)) has accepted Bluebird bio's (BLUE) marketing authorization application for its investigational elivaldogene autotemcel (eli-cel, Lenti-D) gene therapy for the treatment of patients with cerebral adrenoleukodystrophy ((CALD)), a fatal neurodegenerative disease primarily affecting young boys.In July 2020, EMA's advisory group granted an accelerated assessment to eli-cel, potentially...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jefferies Cell Therapy Virtual Summit, Tuesday, October 6, at 2:00 p.m. ET. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcast will be available on the bluebird bio we
Bluebird bio's (BLUE) LentiGlobin, an investigational gene therapy (bb1111) for the treatment of sickle cell disease ((SCD)), was granted eligibility to the Priority Medicines ((PRIME)) program by the EMA.PRIME, akin to Breakthrough Therapy status in the U.S., provides for more intensive guidance on development and accelerated review of the market application. SCD...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that its investigational treatment for sickle cell disease (SCD), LentiGlobin™ for SCD gene therapy (bb1111), was granted eligibility to the Priority Medicines (PRIME) program by the European Medicines Agency (EMA). The EMA’s PRIME initiative provides enhanced support and increased interaction to companies, with the goal of optimizing development plans and speeding regulatory evaluations to potentially bring in